Skyepharma Ltd, formerly Skyepharma PLC, is a drug delivery company engaged in the development of oral and inhalation products. The Company operates as an independent developer of complex pharmaceutical products for global markets. Its principal activities are the generation and development of product and drug delivery technology concepts, involving the application of its inhalation and oral technologies. It operates through the segment of development and supply of pharmaceutical products. It is also involved in the supply of products to its marketing partners, as in the case for flutiform and over seven oral products manufactured in its Lyon Facility. It operates primarily for respiratory applications. Its inhalation products include Relvar Ellipta/Breo Ellipta, Anoro Ellipta and Incruse Ellipta. Its oral products include RAYOS/LODOTRA, Requip Once-a-day, Xatral/Uroxatral, Madopar DR/Prolopa, Sular, ZYFLO CR, Paxil CR, Diclofenacratiopharm Uno, Triglide and Coruno.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: LON:SKP
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: GBX 466.10
- 200 Day Moving Avg: GBX 407.95
- 52 Week Range: GBX 249.25 - GBX 486.25
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Net Margins: 32.70%
- Return on Equity: 79.41%
- Return on Assets: 35.64%
- Average Volume: 316,620 shs.
Frequently Asked Questions for SkyePharma PLC (LON:SKP)
What is SkyePharma PLC's stock symbol?
SkyePharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "SKP."
Who are some of SkyePharma PLC's key competitors?
Some companies that are related to SkyePharma PLC include Johnson & Johnson (JNJ), Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Abbott Laboratories (ABT), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Valeant Pharmaceuticals International (VRX).
How do I buy SkyePharma PLC stock?
Shares of SkyePharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is SkyePharma PLC's stock price today?
MarketBeat Community Rating for SkyePharma PLC (LON SKP)MarketBeat's community ratings are surveys of what our community members think about SkyePharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of SkyePharma PLC stock can currently be purchased for approximately GBX 444.
Earnings History for SkyePharma PLC (LON:SKP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for SkyePharma PLC (LON:SKP)
Current Year EPS Consensus Estimate: $19.75 EPS
Dividend History for SkyePharma PLC (LON:SKP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for SkyePharma PLC (LON:SKP)Insider Trades by Quarter for SkyePharma PLC (LON:SKP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for SkyePharma PLC (LON:SKP)
Latest Headlines for SkyePharma PLC (LON:SKP)
SkyePharma PLC (SKP) Chart for Tuesday, June, 27, 2017